ApoE ε4 Genotype Is Accompanied by Lower Metabolic Activity in Nucleus Basalis of Meynert Neurons in Alzheimer Patients and Controls as Indicated by the Size of the Golgi Apparatus

Journal of Neuropathology and Experimental Neurology

Volumn 63, Issue 2, 2004, Pages 159-169

  Dubelaar, Elizabeth J G ^a,c   Verwer, R W H ^a   Hofman, M A ^a   Van Heerikhuize, J J ^a   Ravid, R ^b   Swaab, D F ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b NETHERLANDS BRAIN BANK   (Netherlands)

^c NONE   (Netherlands)

Author keywords

Alzheimer disease; Apolipoprotein E; Basal nucleus of Meynert; Cholinergic; Golgi Apparatus; Metabolism; Risk factors

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CELL SURFACE RECEPTOR; CHOLINE ACETYLTRANSFERASE; CYSTEINE RICH FIBROBLAST GROWTH FACTOR RECEPTOR; CYSTEINE-RICH FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; NERVE GROWTH FACTOR; SIALOGLYCOPROTEIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CELL METABOLISM; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENOTYPE; GOLGI COMPLEX; HUMAN; HUMAN TISSUE; MALE; MEYNERT BASAL NUCLEUS; MORPHOMETRICS; PRIORITY JOURNAL; RISK FACTOR; CASE CONTROL STUDY; CELL COUNT; CELL SIZE; COMPARATIVE STUDY; CYTOLOGY; GENETICS; HOSPITALIZATION; IMMUNOHISTOCHEMISTRY; METABOLISM; NERVE CELL; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BASAL NUCLEUS OF MEYNERT; CASE-CONTROL STUDIES; CELL COUNT; CELL SIZE; CHOLINE O-ACETYLTRANSFERASE; FEMALE; GENOTYPE; GOLGI APPARATUS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NERVE GROWTH FACTORS; NEURONS; RECEPTORS, CELL SURFACE; RECEPTORS, FIBROBLAST GROWTH FACTOR; SEVERITY OF ILLNESS INDEX; SIALOGLYCOPROTEINS;

EID: 0842331312     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/63.2.159     Document Type: Article

References (40)

1. Kasa P, Rakonczay Z, Gulya K. The cholinergic system in Alzheimer's disease. Prog Neurobiol 1997;52:511-35
2. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403
3. Geula C, Mesulam MM. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb Cortex 1996;6:165-77
4. Strada O, Vyas S, Hirsch EC, et al. Decreased choline acetyltransferase mRNA expression in the nucleus basalis of Meynert in Alzheimer disease: An in situ hybridization study. Proc Natl Acad Sci U S A 1992;89:9549-53
5. Mesulam MM, Mufson EJ, Wainer BH, Levey AI. Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 1983;10:1185-201
6. Smith DE, Roberts J, Gage FH, Tuszynski MH. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci U S A 1999;96:10893-98
7. Swaab DF, Dubelaar EJG, Hofman MA, Scherder EJA, van Someren EJW, Verwer RWH. Brain aging and Alzheimer's disease; use it or lose it. Prog Brain Res 2002;138:343-73
8. Swaab DF. Brain aging and Alzheimer's disease, "wear and tear" versus "use it or lose it". Neurobiol Aging 1991;12:317-24
9. Hammerschlag R, Stone GC, Bolen FA, Lindsey JD, Ellisman MH. Evidence that all newly synthesized proteins destined for fast axonal transport pass through the Golgi apparatus. J Cell Biol 1982;93:568-75
10. Salehi A, Lucassen PJ, Pool CW, Gonatas NK, Ravid R, Swaab DF. Decreased neuronal activity in the nucleus basalis of Meynert in Alzheimer's disease as suggested by the size of the Golgi apparatus. Neuroscience 1994;59:871-80
11. Salehi A, Dubelaar EJG, Mulder M, Swaab DF. Aggravated decrease in the activity of nucleus basalis neurons in Alzheimer's disease is apolipoprotein E-type dependent. Proc Natl Acad Sci U S A 1998;95:11445-49
12. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-23
13. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72
14. Soininen HS, Riekkinen PJ, Sr. Apolipoprotein E, memory and Alzheimer's disease. Trends Neurosci 1996;19:224-28
15. Tol J, Roks G, Slooter AJ, van Duijn CM. Genetic and environmental factors in Alzheimer's disease. Rev Neurol (Paris) 1999;155: S10-S6
16. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
17. Ravid R, Van Zwieten EJ, Swaab DF. Brain banking and the human hypothalamus-factors to match for, pitfalls and potentials. Prog Brain Res 1992;93:83-95
18. Nielsen AS, Ravid R, Kamphorst W, Jorgensen OS. Apolipoprotein E epsilon 4 in an autopsy series of various dementing disorders. J Alzheimers Dis 2003;5:119-25
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44
20. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-39
21. Van de Nes JAP, Kamphorst W, Ravid R, Swaab DF. Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: Amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathol (Berl) 1998;96:129-38
22. Ishunina FA, Unmehopa UU, van Heerikhuize JJ, Pool CW, Swaab DF. Metabolic activity of the human ventromedial nucleus neurons in relation to sex and ageing. Brain Res 2001;893:70-76
23. Mourelatos Z, Gonatas JO, Cinato E, Gonatas NK. Cloning and sequence analysis of the human MG160, a fibroblast growth factor and E-selectin binding membrane sialoglycoprotein of the Golgi apparatus. DNA Cell Biol 1996;15:1121-28
24. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-48
25. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 1983;214:170-97
26. Lilliefors HW. On the Kolmogorov-Smirnov test for normality with mean and variance unknown. JASA 1967;62:399-402
27. Salehi A, Swaab DF. Diminished neuronal metabolic activity in Alzheimer's disease. J Neural Transm 1999;106:955-86
28. Swaab DF, Lucassen PJ, Salehi A, Scherder EJA, van Someren EW, Verwer RWH. Reduced neuronal activity and reactivation in Alzheimer's disease. Prog Brain Res 1998;117:343-77
29. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995;92:12260-64
30. Mielke R, Zerres K, Uhlhaas S, Kessler J, Heiss WD. Apolipoprotein E polymorphism influences the cerebral metabolic pattern in Alzheimer's disease. Neurosci Lett 1998;254:49-52
31. Allen SJ, MacGowan SH, Tyler S, et al. Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neurosci Lett 1997;239:33-36
32. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942-47
33. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752-58
34. Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2000;97:6037-42
35. Deary IJ, Whiteman MC, Pattie A, et al. Cognitive change and the APOE epsilon 4 allele. Nature 2002;418:932
36. DeKosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002;51:145-55
37. Bretsky P, Guralnik JM, Launer L, Albert M, Seeman TE. The role of APOE-epsilon4 in longitudinal cognitive decline: MnacArthur Studies of Successful Aging. Neurology 2003;60:1077-81
38. Hoyer S, Oesterreich K, Wagner O. Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type? J Neurol 1988;235:143-38
39. Braak H, Braak E. Neurofibrillary changes confined to the entorhinal region and an abundance of cortical amyloid in cases of presenile and senile dementia. Acta Neuropathol 1990;80:479-86
40. Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp Neurol 1998;153152-55.